Alzheimer's Disease Clinical Trial
Official title:
Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)
Alzheimer's disease (AD) and Lewy body's dementia (LBD) are two frequent neurodegenerative
pathologies. They differ in their expression, their evolution but share same features which
make their diagnosis uneasy.
Constructional apraxia has been described in both disease.The underlying mechanisms have
been less studied and could be different in AD and LBD.
The definition of the constructional apraxia is purely descriptive and few models are
inconclusive.
It is admitted that drawing tasks involve visuo-perceptive and visuo-spatial abilities,
executive functions and working memory as well as purely "constructive" skills.
Regarding to different studies, visuo-perceptive abilities are more severely impaired in LBD
than in AD and are considered as an early onset sign of the disease.
Executive functions deficits are documented in AD and LDB and could contribute to the
drawing impairment.
It is possible to compensate the planning disorders in giving patient the best strategy to
use.
If drawing impairment persists, they should result of others mechanisms like
visuo-perception, visuo-spatial or constructive deficits.
The investigators suggest that giving the best planning strategy will help more AD patients
who are supposed to fail in raison of an executive impairment, than the LDB group who is
supposed to present visuo-perceptive deficits. An MRI will be proposed to study the cerebral
areas involved in constructional apraxia.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years and older |
Eligibility |
Inclusion Criteria: - Alzheimer's disease or Lewy bodies dementia - = 45 years - the cognitive impairment is mild to moderate - French speaker - a caregiver is present - An informed consent is signed by the patient and the p.i. Exclusion Criteria: - MRI contraindication - Other neurological disease (FTD, brain tumor, vascular disease…) - Psychiatric disease (Schizophrenia, major depression, psychotic disorders, melancholia…) - Patient who doesn't want to be informed in case of the discovery of an abnormality - View or audition deficits, or motor disability which can interfere with the cognitive testing - Patient participating to an exclusive protocol or in the period of exclusion - Pregnant woman - Person under an administrative or legal measure of liberty privation - Person under a legal measure of protection or under administrative supervision - Person unable to give his consent |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | Hôpitaux Universitaires de Strasbourg | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Score obtained at the Rey figure test with a planning strategy help by LBD patients compared to the score obtained by AD patients. | At inclusion | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02309723 -
How Beta-amyloid Imagining Influences Clinician Diagnosis and Management of Hypothetical Patients With Cognitive Complaints
|
N/A |